Navigation Links
DFG establishes 9 new research units
Date:2/11/2011

roup also intends to examine the relevance these mathematical tools have for the physics of complex structured materials, thus linking the group's research to condensed matter and statistical physics. The physicists involved will focus (among other topics) on analysing the distribution of galaxies within the universe and on studying mesoscopic structures in microemulsions. They will do so using the stochastic methods developed. The planned research, which includes a project involving researchers from Denmark, is particularly significant due to the exceptionally varied application opportunities for stochastic geometry in the analysis, modelling and simulation of microscopic and macroscopic geographical structures.

(Coordinating Institution: The Karlsruhe Institute of Technology (KIT): Coordinator: Professor Gnter Last)

A new Research Unit involving researchers working in the synthetic, spectroscopic and theoretical fields aims to explore and utilise the far-reaching opportunities provided by laser- and synchrotron-based radiation sources in answering chemical and biological questions. As its name ["Dynamik von Elektronentransferprozessen an bergangsmetallzentren in biologischen und bioanorganischen Systemen"] indicates, the group will investigate the "Dynamics of Electron Transfer Processes at Transition Metal Centres in Biological and Bioinorganic Systems". The group's research will focus primarily on time-resolved measurements. It has not, until now, been possible to perform these using conventional radiation sources. The group will examine chemical model systems which have already been well-researched in themselves, but which are expected to provide considerable new insights with the application of the new methods. The planned experiments, which will be carried out at various locations including Deutsche Elektronen-Synchotron (DESY), are intended to provide strong impetus to both the bioinorganic field and to biological research into metalloenzymes.
'/>"/>

Contact: Marco Finetti
marco.finetti@dfg.de
49-228-885-2230
Deutsche Forschungsgemeinschaft
Source:Eurekalert

Page: 1 2 3 4 5 6 7

Related biology news :

1. Rice University establishes National Corrosion Center
2. UBC study establishes formula for predicting climate change impact on salmon stocks
3. The last supper of the hominids establishes the times they lived at the sites
4. $29.4 million grant establishes CTSI at NYU in partnership with Health and Hospitals Corporation
5. MU research team establishes family tree for cattle, other ruminants
6. March of Dimes establishes 2 new perinatal bioethics awards
7. TGen Drug Development establishes European footprint
8. DFG establishes 10 new research units
9. Innovalight Establishes New Record With Silicon Ink Solar Cells
10. Covance Establishes New Discovery & Translational Services Group
11. Covance Establishes New Discovery & Translational Services Group
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... biologists, led by Clemson University associate professor Andrew S. ... will pave the way for novel anti-fouling paint for ... and industrial applications. , The team,s findings, published in ... larval stage of barnacles that attaches to a wide ... material that acts as an underwater heavy-duty adhesive. , ...
(Date:7/30/2014)... Portland Press Limited today announced an across-the-board increase ... , The 2013 InCites Journal Citation Reports (Thomson ... Biochemical Journal , Essays in Biochemistry ... Bioscience Reports all received increases in their ... Biochemical Society and published by Portland Press Limited. ...
(Date:7/30/2014)... A professor from Wayne State University,s College of ... National Science Foundation for the project, "Nanoparticle-directed synthesis ... National Science Foundation, nanotechnology is the creation and ... novel properties and functions. A major bottleneck in ... methods that connect different functional materials into one ...
Breaking Biology News(10 mins):Study: Marine pest provides advances in maritime anti-fouling and biomedicine 2Across-the-board Impact Factor increases for Portland Press Limited 2NSF grant to Wayne State supports new concept for manufacturing nanoscale devices 2
... have created the first three-dimensional living tissue model, complete ... therapeutics to combat brain tumors. The 3-D model gives ... tissue cultures. The researchers created a glioma, or ... surrounds it. In a series of experiments, the team ...
... have succeeded in changing the genetic material of cancer ... in nanosurgery opens the door to new medical applications, ... A light scalpel to treat cancerous cells, The ... team uses a femtosecond laser (a laser with ultra-short ...
... Resolving the world,s major challenges whether climate change, ... scarcity requires a sweeping shift in our approach ... leading scientists told European policy makers today during ... and Societal Challenges for our Unstable Earth" (RESCUE). ...
Cached Biology News:Researchers make living model of brain tumor 2Europe needs a 'RESCUE' revolution 2Europe needs a 'RESCUE' revolution 3
(Date:7/30/2014)... , July 30, 2014  Orexigen Therapeutics, Inc. (Nasdaq: ... the Day 180 List of Outstanding Issues (LOI) from ... Human Use (CHMP) for the NB32 Marketing Authorization Application ... is an investigational drug candidate being evaluated for weight ... Day 120 time point were adequately addressed by the ...
(Date:7/30/2014)...  AtheroNova Inc. (OTCBB: AHRO), a biotech company ... to safely regress atherosclerotic plaque and improve lipid ... CardioNova, has accomplished first dosing of subjects for ... compound, AHRO-001.  This Phase 1b trial will be ... trial completed in February 2014, in which patients ...
(Date:7/30/2014)... July 30, 2014 Vala Sciences ... U.S. Environmental Protection Agency (EPA). This new contract ... toxicity models, including tests designed to assess the ... the formation of connections between neurons (synapses), which ... and synapse formation by environmental pollutants likely contributes ...
(Date:7/29/2014)... July 30, 2014 SoundConnect ... collaboration company, is proud to announce the strategic ... positions in their Boston, Charleston and Atlanta offices. ... the increased demand for hosted solutions, collaboration and ... and reduce cost. , SoundConnect was founded in ...
Breaking Biology Technology:Orexigen Receives CHMP Day 180 List of Outstanding Issues 2Orexigen Receives CHMP Day 180 List of Outstanding Issues 3AtheroNova Announces Milestone with Initiation of Phase 1b Clinical Trial of AHRO-001 2AtheroNova Announces Milestone with Initiation of Phase 1b Clinical Trial of AHRO-001 3AtheroNova Announces Milestone with Initiation of Phase 1b Clinical Trial of AHRO-001 4U.S. Environmental Protection Agency (EPA) Awards Vala Sciences a Second ToxCast Contract 2U.S. Environmental Protection Agency (EPA) Awards Vala Sciences a Second ToxCast Contract 3SoundConnect Organization and Culture is Evolving 2
... July 14 Bio-Optronics, Inc., a leader in healthcare workflow ... software solution that can simultaneously handle the most intricate scheduling ... staff schedules. , , Physician ... , Bio-Optronics President & CEO, ...
... , HALIFAX, NS, July 14 /PRNewswire/ - ImmunoVaccine ... entered into an agreement to exclusively license seven ... company. These proprietary antigens specifically target breast, ovarian ... antigens with its DepoVax(TM) delivery platform to develop ...
... , , TAMPA, Fla., July ... on the research and development of cancer immunotherapies, announces that the ... its dendritic cell therapy. , , ... I/II clinical trial testing the safety and efficacy of its immunotherapy ...
Cached Biology Technology:NEW Momentum(TM) Physician and Staff Scheduling Software for Imaging Centers, OB/GYN, and Other Specialty Practices Improves Productivity and Equity in Scheduling 2ImmunoVaccine Technologies Licenses Immunotope's Breast, Ovarian and Prostate Cancer Antigens 2Significant Milestone Marks the Beginning of FDA-Authorized Breast Cancer Trial 2Significant Milestone Marks the Beginning of FDA-Authorized Breast Cancer Trial 3